Showing 4641-4650 of 6977 results for "".
- Naftifine Gel Found Effective for Moccasin-Type Tinea Pedishttps://practicaldermatology.com/news/20130307-naftifine_gel_found_effective_for_moccasin-type_tinea_pedis/2459600/New data has found that the topical antifungal agent naftifine hydrochloride gel 2% (Merz North America) is both efficacious and tolerable in the treatment for interdigital-type and moccasin-type Tinea pedis. In a poster presented at the AAD Annual Meeting in Miami, the authored sounds that naftifin
- Medical Entrepreneur Symposium: Registration Open, Sponsors Invitedhttps://practicaldermatology.com/news/20130226-medical_entrepreneur_symposium_registration_open_sponsors_invited/2459606/The 2nd Annual The Medical Entrepreneur Symposium for physicians, office managers and physician entrepreneurs, to be held in Delray Beach, FL April 19-21, is expected to attract over 150 healthcare (and healthcare related) professionals an
- New Survey: Social Media is a Major Influence on Elective Surgeryhttps://practicaldermatology.com/news/20130225-new_survey_social_media_is_a_major_influence_on_elective_surgery/2459611/Social media is leading consumers to have a more self-critical eye, according to a new survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). The annual poll of 752 of the organization's board-certified facial plastic surgeons found that there was a 31% increase in req
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated the
- Survey Data Highlight Expenses and Access-to-Care for Psoriasis Patientshttps://practicaldermatology.com/news/20130208-survey_data_highlight_expenses_and_access-to-care_for_psoriasis_patients/2459618/New findings from the National Psoriasis Foundation (NPF) indicate that patients with psoriasis and psoriatic arthritis patients spend more than $2,500 per year in out-of-pocket costs for their disease. In an analysis of eight years of data to determine access-to-care issues and out-of-pocket costs
- Aesyntix Partners With Sentéhttps://practicaldermatology.com/news/20130125-aesyntix_partners_with_sent/2459626/Aesyntix Physician Network (APN), a group purchasing organization and subsidiary of Aesyntix Health, Inc., entered into an agreement with Senté, Inc., a privately held cosmeceutical company that develops differentiated medical skincare pro
- Women's Dermatologic Society Event January 15https://practicaldermatology.com/news/20130111-womens_dermatologic_society_event_january_15/2459640/The Women's Dermatologic Society, sponsored by Glytone, will hold a “Look Before You Leap” Media Day 2013 on January 15, a series of desk-side appointments with the editorial community focusing on the pitfalls, complications, problems, and myths surrounding skin care and dermatology topics. Founded
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Dermatology Partnerships Exploredhttps://practicaldermatology.com/news/20121115-dermatology_partnerships_explored/2459681/Research and Markets has added the "Dermatology Partnering Terms and Agreements" report to their offering. This report provides a detailed understanding and analysis of how and why companies enter dermatology